Sintilimab, created by the company, represents a significant advance in cancer therapy . This protein approach is a PD-1 inhibitor , intended to unleash the body's response against tumors . Research assessments have demonstrated encouraging results , particularly in combination with other medicines , displaying potential for boosting longevity rate